Treatment of acute coronary syndrome with GLP-1
AssigneeAmylin Pharmaceuticals, Inc.
InventorsThomas R. Coolidge, Mario Ehlers
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.
Claims47
A method of treating a patient suffering from acute coronary syndrome, comprising administering to the patient a therapeutically effective amount of a GLP-1 molecule, wherein said patient is not suffering from a Q-wave myocardial infarction.
A method for treatment of a patient, comprising administering to said individual a therapeutically effective amount of a GLP-1 molecule, wherein said administration is after the onset of one or more of the following symptoms:
- chest pain lasting longer than 15 minutes, chest pain at rest, chest pain following minimal exertion, nausea, shortness of breath, palpitations, or dizziness.
A method for treating a patient suffering from stable angina, comprising administration of a GLP-1 molecule.
A method for performing angioplasty on a patient in need thereof, comprising administering a GLP-1 molecule to the patient during the angioplasty procedure.
A method for treatment of a patient with ischemic heart disease, or is at risk for developing ischemic heart disease, and who exhibits one or more of the following symptoms:
- nausea, shortness of breath, palpitations and dizziness, and further wherein said patient does not exhibit chest pain, comprising administering to the patient a therapeutically effective amount of a GLP-1 molecule, wherein said patient is not suffering from a Q-wave myocardial infarction.
A method for increasing the time during which thrombolytic therapy will be effective following the first symptom of cardiac distress, comprising administering a therapeutically effective amount of a GLP-1 molecule after the onset of one or more of the following symptoms:
- chest pain lasting longer than 15 minutes, chest pain at rest, chest pain following minimal exertion, nausea, shortness of breath, palpitations, or dizziness.
A kit comprising one or more doses of a GLP-1 molecule, said kit comprising a device selected from the group consisting of an insulin-type syringe, a “pen” injector that delivers a metered dose, a needle-less injector, a liquid-formulation, a dry-powder inhaler, a buccal tablet, and a sublingual tablet.
Dependencies are inferred from the claim text.